touchIMMUNOLOGY meets Dr Pia Kvistborg at the Virtual 2020 ESMO Congress to discuss the presentation of her late-breaking abstract ‘The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01’ (LBA73) and initial findings from her recent study.
- How did your collaboration with Andrea Cossarizza on SARS-CoV-2 come about? (0:12)
- How have you applied cancer research technology to elucidate structural components of the SARS-CoV-2 virus? (1:04)
- Could you give us an overview of the aims and design of your recent study? (2:40)
- What were the main findings of your study? (4:48)
- What are the implications of these findings on vaccine design? (10:55)
Speaker Disclosure: Pia Kvistborg has nothing to disclose in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In COVID-19
Nancy Reau, DDW 2021: Hepatic Manifestations of COVID-19
It was a pleasure to speak with Prof. Nancy Reau (Rush Medical College, Chicago, IL, USA) about the hepatic manifestations of COVID-19 infection. Her presentation entitled ‘HEPATIC MANIFESTATIONS OF COVID-19: IS THERE CAUSE FOR CONCERN?’ was given at DDW, 21-23 May 2021 May 2021. Questions Could you give us a brief overview of the spectrum […]
Corey A Siegel: SARS-CoV-2 Vaccination for Patients with IBD
We were delighted to talk to Corey Siegel (Dartmouth-Hitchcock Medical Center, Lebanon, NH, US) around the IOIBD consensus statement on SARS-CoV-2 vaccination in patients with IBD. Questions What issues were discussed at the consensus meeting of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) regarding the safety and effectiveness of SARS-CoV-2 vaccination […]
John H Stone, ACR 2020: Tocilizumab for COVID-19 Infection
It was a pleasure to be able to speak with John Stone (Massachusetts General Hospital, Boston, MA, USA) about the findings from his investigations into tocilizumab as a therapy for COVID-19 infection. His presentation entitled ‘Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial’ (Abstract Number: L07) was presented at the ACR Convergence, 5-9 November. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!